Arrowhead Shares Pop on Early Clinical Data for Hepatitis B Drug
Summary
Arrowhead Pharmaceuticals on Thursday made public select initial data from an early-stage clinical study of a hepatitis B drug it’s developing, sending the company’s stock price (NASDAQ: ARWR ) to a four-year high.Arrowhead shared data from a study aimed at evaluating the safety and tolerability of a drug candidate it’s developing to treat chronic hepatitis B virus (HBV).An estimated 257 million people worldwide are living with HBV infection, which can lead to cirrhosis and liver cancer, according to The World Health Organization.Arrowhead is among the drug developers seeking to commercialize therapies using RNA interference (RNAi), which involves shutting down, or “silencing” a gene before it can produce a potentially harmful protein.Arrowhead said Bruce Given, the company’s chief operating officer, will present data from the ARO-HBV study on Friday at the World Gastroenterologists Summit in Auckland, New Zealand.
Classifications
AskAI Classifications
LabelsLinked Companies
